Metraipolis › archive › dc_ef56def9bf0b
Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights — Europe PMC PMID:40062406
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40062406
- DOI
- 10.1080/19490976.2025.2477255
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T13:17:22.882Z
- SHA-256 of the archived text
c8456b31d7f3f72a4477622d286d3d76a7ba55c12fccacb239e7c80829802659- Stable URL of this page
https://metraipolis.com/documento/dc_ef56def9bf0b
How to cite
Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights — Europe PMC PMID:40062406 — Europe PMC (en), https://europepmc.org/article/MED/40062406 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ef56def9bf0b (Metraipolis archive dc_ef56def9bf0b, sha256 c8456b31d7f3f72a4477622d286d3d76a7ba55c12fccacb239e7c80829802659)
BibTeX
@misc{dcef56def9bf0b,
title = {Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights — Europe PMC PMID:40062406},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40062406},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ef56def9bf0b; sha256 c8456b31d7f3f72a4477622d286d3d76a7ba55c12fccacb239e7c80829802659},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40062406. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Microbiota transplant therapy is an emerging therapy for inflammatory bowel disease, but factors influencing its efficacy and mechanism remain poorly understood. In this narrative review, we outline key elements affecting therapeutic outcomes, including donor factors (such as age and patient relationship), recipient factors, control selection, and elements impacting engraftment and its correlation with clinical response. We also examine potential mechanisms through inflammatory bowel disease trials, focusing on the interplay between the microbiota, host, and immune system. Finally, we briefly explore potential future directions for microbiota transplant therapy and promising emerging treatments. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: Gut microbes, 2025 (prima pubblicazione 2025-03-10). Identificativi: PMID 40062406 · PMCID PMC11901402 · DOI 10.1080/19490976.2025.2477255. Parole chiave degli autori: Ulcerative colitis; Inflammatory Bowel Disease; Crohn’s Disease; Microbiome; Fecal Microbiota Transplantation; Microbiota Transplant Therapy. Descrittori MeSH principali: Inflammatory Bowel Diseases; Gastrointestinal Microbiome; Fecal Microbiota Transplantation. Pagina: https://europepmc.org/article/MED/40062406 — https://doi.org/10.1080/19490976.2025.2477255. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T11:32:36.062Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.